83 related articles for article (PubMed ID: 9053603)
1. [New therapeutic methods against rheumatoid arthritisp6. Antibodies against TNFalpha significant for the progress].
Bondeson J
Lakartidningen; 1997 Jan; 94(1-2):42-5. PubMed ID: 9053603
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).
Bondeson J; Maini RN
Int J Clin Pract; 2001 Apr; 55(3):211-6. PubMed ID: 11351775
[TBL] [Abstract][Full Text] [Related]
3. [Blockade of TNFalpha--new therapeutic principle in severe rheumatoid arthritis].
Larsson P; Bratt J; Harju A; van Vollenhoven R; Klareskog L
Lakartidningen; 2001 Feb; 98(8):828-31. PubMed ID: 11265568
[TBL] [Abstract][Full Text] [Related]
4. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
[TBL] [Abstract][Full Text] [Related]
5. Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action.
Feldmann M; Brennan FM; Williams RO; Elliott MJ; Maini RN
J Inflamm; 1995-1996; 47(1-2):90-6. PubMed ID: 8913935
[TBL] [Abstract][Full Text] [Related]
6. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
Sokka T; Pincus T
Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
[TBL] [Abstract][Full Text] [Related]
7. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
Reumatizam; 2007; 54(1):16-9. PubMed ID: 18450272
[TBL] [Abstract][Full Text] [Related]
8. A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis.
Marinova-Mutafchieva L; Williams RO; Mauri C; Mason LJ; Walmsley MJ; Taylor PC; Feldmann M; Maini RN
Arthritis Rheum; 2000 Mar; 43(3):638-44. PubMed ID: 10728758
[TBL] [Abstract][Full Text] [Related]
9. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis.
Maurice MM; van der Graaff WL; Leow A; Breedveld FC; van Lier RA; Verweij CL
Arthritis Rheum; 1999 Oct; 42(10):2166-73. PubMed ID: 10524689
[TBL] [Abstract][Full Text] [Related]
10. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
11. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN
Novartis Found Symp; 2004; 256():53-69; discussion 69-73, 106-11, 266-9. PubMed ID: 15027483
[TBL] [Abstract][Full Text] [Related]
12. TNF inhibitors in the treatment of arthritis.
Lorenz HM
Curr Opin Investig Drugs; 2000 Oct; 1(2):188-93. PubMed ID: 11249572
[TBL] [Abstract][Full Text] [Related]
13. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
Fleischmann R; Shealy D
Mol Interv; 2003 Sep; 3(6):310-8. PubMed ID: 14993463
[No Abstract] [Full Text] [Related]
14. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
Cairns AP; Taggart AJ
Ulster Med J; 2002 Nov; 71(2):101-5. PubMed ID: 12513005
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
Choy E
Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
[TBL] [Abstract][Full Text] [Related]
17. Biologic therapy for early rheumatoid arthritis: the latest evidence.
Castro-Rueda H; Kavanaugh A
Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
[TBL] [Abstract][Full Text] [Related]
18. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.
Ulfgren AK; Andersson U; Engström M; Klareskog L; Maini RN; Taylor PC
Arthritis Rheum; 2000 Nov; 43(11):2391-6. PubMed ID: 11083259
[TBL] [Abstract][Full Text] [Related]
19. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
Gerlag DM; Tak PP
Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
[TBL] [Abstract][Full Text] [Related]
20. [TNFalpha inhibitors for the treatment of rheumatoid arthritis].
Sany J; Kaiser MJ
Ann Med Interne (Paris); 2002 Feb; 153(1):34-40. PubMed ID: 11994688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
